klhl41a Antibody

What is KLHL41 and what are its key structural characteristics?

KLHL41 (also known as KBTBD10, SARCOSIN, or Kelch-related protein 1) is a 606-amino acid protein with a molecular weight of approximately 68 kDa . Structurally, KLHL41 contains three conserved domains:

• BTB (Broad-Complex, Tramtrack, and Bric-a-brac) domain - located at the N-terminus

• BACK (BTB and C-terminal Kelch) domain - positioned centrally

• Kelch repeats - found in the C-terminal region

The BTB domain mediates protein-protein interactions, particularly homodimerization and heterodimerization with other BTB-containing proteins. This domain is critical for KLHL41's interaction with the CUL3 ubiquitin ligase complex . The Kelch repeats form a β-propeller structure that functions as a protein-binding interface for substrate recognition.

Up to two isoforms have been reported for KLHL41, with subcellular localization primarily in the endoplasmic reticulum and cytoplasm .

What applications are KLHL41 antibodies commonly used for?

KLHL41 antibodies are utilized across several experimental techniques:

When selecting an antibody, researchers should consider whether their experimental design requires detection of specific domains or full-length KLHL41 . Antibodies targeting different regions (N-terminal versus C-terminal) may yield different staining patterns, with C-terminal antibodies often producing lower background in immunofluorescence studies .

How is KLHL41 distributed across tissues and development stages?

KLHL41 shows strong tissue-specific expression patterns:

• Highest expression: skeletal muscle and diaphragm

• Expression increases during myogenic differentiation in C2C12 cells

• In mouse models, KLHL41 expression is detectable throughout embryonic and postnatal development

Within skeletal muscle, KLHL41 predominantly localizes to the I-bands of sarcomeres and perinuclear regions . In transverse sections, it appears in a distinctive ring pattern around myofibrils, often colocalizing with ryanodine receptors (RYR1), indicating association with the sarcoplasmic reticulum .

The KLHL41 marker can also be used to identify Myo-Medullary Thymic Epithelial Cells, providing utility beyond muscle research .

How do KLHL41 antibodies help elucidate the nonproteolytic functions of this protein in sarcomere stabilization?

Unlike many Kelch family proteins that function as substrate adaptors for E3 ubiquitin ligase complexes targeting proteins for degradation, KLHL41 has been shown to stabilize certain sarcomeric proteins, particularly nebulin . This unique function makes KLHL41 antibodies valuable tools for investigating protein stabilization mechanisms.

Methodological approach for studying KLHL41's stabilizing function:

• Co-immunoprecipitation with KLHL41 antibodies: Enables identification of KLHL41 interacting partners such as nebulin fragments (NEBfrag), NRAP, and filamin-C (FLNC)

• Tandem affinity purification (TAP): Using tagged KLHL41 followed by mass spectrometry has revealed multiple structural components of the sarcomere as binding partners, including nebulin, NRAP, filamin-C, and KLHL40

• Comparative western blot analysis: KLHL41 antibodies can be used to compare protein levels in wild-type versus KLHL41 knockout tissues to identify which sarcomeric proteins are dependent on KLHL41 for stability

Research using these approaches has revealed that KLHL41 functions as a molecular chaperone, preventing aggregation and degradation of essential sarcomeric components, particularly nebulin .

What are the technical considerations when using KLHL41 antibodies in studies of nemaline myopathy?

Nemaline myopathy is a congenital muscle disorder characterized by muscle weakness and the presence of rod-like (nemaline) bodies in muscle fibers. Mutations in KLHL41 have been identified as causative for certain forms of this disease .

When investigating nemaline myopathy using KLHL41 antibodies, researchers should consider:

• Antibody selection: Use antibodies validated on both normal and pathological tissue samples. Different KLHL41 mutations may affect epitope availability, so employing antibodies targeting different regions of the protein is advisable

• Control selection: Include appropriate controls, including tissue from healthy individuals and, if possible, tissues from patients with nemaline myopathy caused by mutations in other genes (e.g., nebulin, actin, tropomyosin)

• Quantification methods: Employ quantitative western blotting to accurately assess changes in KLHL41 protein levels. In affected tissues with KLHL41 mutations, protein levels are often greatly reduced but rarely completely absent

• Microscopy optimization: For immunofluorescence studies of nemaline bodies, confocal microscopy with z-stack acquisition provides the most accurate assessment of protein localization and colocalization with other sarcomeric markers

• Complementary approaches: Combine immunostaining with electron microscopy to correlate KLHL41 localization with ultrastructural abnormalities such as Z-line streaming and nemaline body formation

How can researchers distinguish between KLHL41 and the closely related KLHL40 protein?

KLHL40 and KLHL41 share high structural similarity and both are implicated in nemaline myopathy, yet they have distinct functions and binding partners . Distinguishing between these proteins requires careful antibody selection and experimental design:

• Specific antibody validation: Validate antibody specificity using tissues from KLHL41 knockout and KLHL40 knockout models separately

• Differential localization analysis: While both proteins associate with the sarcoplasmic reticulum, detailed immunofluorescence studies reveal that KLHL40 and KLHL41 have overlapping but not identical localization patterns

• Functional differentiation by substrate stabilization:

  • KLHL41 preferentially stabilizes nebulin over LMOD3

  • KLHL40 strongly stabilizes both nebulin and LMOD3

  This functional difference can be detected through co-expression studies in heterologous cell systems (e.g., COS-7 cells) followed by western blot analysis

• Co-immunoprecipitation studies: Using antibodies against one protein (e.g., KLHL41) can capture complexes containing both proteins, as they can form heterodimers through their BTB domains

What role does poly-ubiquitination play in KLHL41 function, and how can this be investigated?

Intriguingly, unlike the typical scenario where ubiquitination targets proteins for degradation, poly-ubiquitination of KLHL41 is required for its stabilizing activity on nebulin . This represents a novel mechanism for protein function regulation that can be studied using:

• Co-expression of ubiquitin mutants: Expressing ubiquitin mutants (particularly K48R) in cell models reveals that K48-linked poly-ubiquitination is crucial for KLHL41's ability to stabilize nebulin

• Ubiquitination assays: Using KLHL41 antibodies to immunoprecipitate the protein followed by western blotting with anti-ubiquitin antibodies can reveal the extent and type of KLHL41 ubiquitination

• Domain mapping: By creating deletion mutants of KLHL41 lacking specific domains (BTB, BACK, or Kelch repeats), researchers can identify regions required for both ubiquitination and substrate stabilization

• Proteasome inhibition studies: Treatment with proteasome inhibitors can help distinguish between ubiquitination for degradation versus non-degradative functions

Experimental data shows that overexpression of a lysine-less ubiquitin mutant (Ub-K0) collapsed high molecular bands of KLHL41 corresponding to poly-ubiquitinated forms and prevented the stabilization of nebulin fragments by KLHL41 .

What are the optimal methods for using KLHL41 antibodies in multiplex immunofluorescence studies?

Multiplex immunofluorescence allows simultaneous detection of multiple proteins and is particularly valuable for studying KLHL41's relationships with other sarcomeric proteins. Recommended methodology includes:

• Antibody pairing optimization:

  • For co-staining with sarcomeric markers, use rabbit polyclonal anti-KLHL41 antibodies with mouse monoclonal antibodies against sarcomeric proteins

  • When studying KLHL41 with other BTB-Kelch proteins, consider species cross-reactivity and use directly conjugated antibodies when possible

• Sample preparation:

  • For cultured myofibers: Use mouse flexor digitorum brevis (FDB) cultured myofibers

  • For tissue sections: 8-10 μm cryosections from flash-frozen skeletal muscle samples yield optimal results

• Z-stack acquisition by confocal microscopy: Essential for accurate assessment of colocalization in three dimensions, particularly important given KLHL41's distribution around myofibrils

• Markers for colocalization studies:

  • Ryanodine receptors (RYR1) - for sarcoplasmic reticulum localization

  • α-actinin - for Z-line identification

  • Myosin heavy chain - for A-band identification

• Analysis of both longitudinal and transverse sections: Provides complementary information about KLHL41's distribution within muscle architecture

What are common challenges when using KLHL41 antibodies and how can they be addressed?

Researchers using KLHL41 antibodies may encounter several technical challenges:

For western blot applications specifically, researchers should note that KLHL41 appears at approximately 68 kDa, but ubiquitinated forms may appear as higher molecular weight bands .

How can researchers validate the specificity of KLHL41 antibodies?

Thorough validation of KLHL41 antibodies is essential for reliable research outcomes:

• Use of genetic models: Tissues from KLHL41 knockout mice provide the gold standard negative control; KLHL41 protein is greatly reduced or absent in these samples by both western blot and immunofluorescence

• Peptide competition assays: Pre-incubation of the antibody with the immunizing peptide should abolish specific signals

• Multiple antibody comparison: Use antibodies raised against different regions of KLHL41 (N-terminal vs. C-terminal) to confirm consistent detection patterns

• Heterologous expression systems: Overexpression of tagged KLHL41 in cell lines provides a positive control for antibody specificity

• RNA interference correlation: Correlation of protein levels detected by antibodies with mRNA knockdown efficiencies provides additional validation

• Mass spectrometry validation: For immunoprecipitation applications, confirming pulled-down proteins by mass spectrometry provides definitive validation

What emerging applications of KLHL41 antibodies show promise for advancing our understanding of muscle biology?

Several cutting-edge approaches using KLHL41 antibodies are expanding our understanding of muscle biology:

• Proximity ligation assays: These can detect and visualize protein interactions between KLHL41 and its binding partners with nanometer resolution in situ, revealing the spatial organization of these interactions within muscle cells

• Single-molecule localization microscopy: Super-resolution techniques can provide unprecedented detail about KLHL41's organization within the sarcomeric structure

• In vivo imaging: Combination of KLHL41 antibodies with cleared tissue techniques allows three-dimensional visualization of protein distribution across whole muscle samples

• Temporal analysis of KLHL41 dynamics: Live-cell imaging using fluorescently tagged nanobodies derived from KLHL41 antibodies may reveal the dynamic behaviors of this protein during myogenesis and in response to muscle stress

• Multi-omics integration: Correlating KLHL41 antibody-based proteomics with transcriptomics and metabolomics can provide systems-level insights into KLHL41's role in muscle homeostasis

These approaches promise to advance our understanding of how KLHL41 contributes to sarcomere stability and how its dysfunction leads to nemaline myopathy and potentially other muscle disorders.

How can KLHL41 antibodies contribute to therapeutic development for nemaline myopathy?

While primarily research tools, KLHL41 antibodies may contribute to therapeutic development through:

• Disease mechanism elucidation: Detailed understanding of how KLHL41 stabilizes nebulin and other sarcomeric proteins can inform therapeutic strategies aimed at compensating for KLHL41 dysfunction

• Biomarker development: KLHL41 antibodies can help identify potential biomarkers for disease progression or treatment response

• Therapeutic screening platforms: Cell-based assays using KLHL41 antibodies can screen for compounds that enhance KLHL41 stability or function, or that bypass KLHL41 to stabilize its substrates directly

• Gene therapy validation: For gene replacement approaches, KLHL41 antibodies provide essential tools to confirm successful expression and appropriate localization of the therapeutic protein

• Protein stabilization strategies: Understanding how KLHL41's poly-ubiquitination contributes to its chaperone-like function may inspire novel therapeutic approaches for protein stabilization in various disorders

The unique nonproteolytic function of KLHL41 represents a paradigm shift in our understanding of Kelch proteins and ubiquitination, potentially opening new therapeutic avenues for muscle disorders characterized by protein instability.